Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients

PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 18, 2022

Primary Completion Date

August 31, 2024

Study Completion Date

December 31, 2024

Conditions
Breast CancerNeuroendocrine TumorsNeuroendocrine CarcinomaNeuroendocrine Carcinoma MetastaticLymphomaSarcoma
Interventions
DRUG

18F-FDG

Injection of 4 MBq/kg of 18F-FDG followed by dynamic positron emission tomography (PET) imaging

DRUG

Injection of hyperpolarized [1-13C]Pyruvate

Injection of one bolus of 0.43 ml/kg of approximately 250 mM hyperpolarized \[1-13C\]Pyruvate followed by magnetic resonance spectroscopy (MRS) / magnetic resonance spectroscopy imaging (MRSI). After a 5-30 min pause, injection of a second bolus of 0.43 ml/kg of approximately 250 mM hyperpolarized \[1-13C\]Pyruvate followed by MRS / MRSI.

PROCEDURE

PET/MR/MRS/MRSI scanning

Regional dynamic PET acquisition for up to 90 minutes following 18F-FDG injection is performed focused on a region-of-interest (ROI). Anatomical magnetic resonance imaging (MRI) is performed in the ROI, including diffusion weighted imaging (DWI) and contrast enhanced imaging (DCE). MRS/MRSI is performed following the injections of hyperpolarized \[1-13C\]Pyruvate.

Trial Locations (1)

2100

Rigshospitalet, Copenhagen

All Listed Sponsors
lead

Rigshospitalet, Denmark

OTHER